Pay in 4 interest-free payments of $5.30 Learn more
Ships within 48 hours · Estimated delivery Aug 11 - Aug 16
Immediate medical attention is necessary if lightheadedness is accompanied by: Chest pain, pressure, or tightness Severe shortness of breath or difficulty breathing Irregular or rapid heartbeat (palpitations) Severe headache, particularly if sudden onset Slurred speech, facial drooping, or weakness on one side of the body Loss of consciousness or fainting episodes Confusion or altered mental status Seizure activity These symptoms may indicate serious cardiovascular or neurological events requiring emergency evaluation
Tirzepatide : Similar to Semaglutide, this medication works on GLP-1 and GIP (gastric inhibitory polypeptide) receptors, resulting in more comprehensive effects on insulin regulation and fat metabolism
Tirzepatide (Mounjaro, Zepbound) targets two pathways (GLP-1 and GIP), producing greater weight loss in head-to-head studiesroughly 20% body weight loss on tirzepatide vs 15% on semaglutide
Who Is BPC-157 For
AHI reduction: Tirzepatide 15mg reduced apnea-hypopnea events by approximately 25-30 per hour vs 5 per hour for placebo Responder rate: Around 42% of tirzepatide participants achieved complete or near-complete resolution of sleep apnea events Weight loss: Average 18% body weight reduction accompanied the AHI improvements, consistent with SURMOUNT-1 data at comparable doses Source: Malhotra et al., NEJM 2024 Sleep Apnea Dosing vs Weight Loss Dosing The titration schedule is the same for both indications
Tirzepatide targets two receptors (GLP-1 and GIP)
